• Increase font size
  • Default font size
  • Decrease font size
Home HPV and Men HPV and Men Studies Show HPV Vaccine Effective with Gay Men and Older Women

Studies Show HPV Vaccine Effective with Gay Men and Older Women

E-mail Print PDF

Merck says data from two studies show its HPV vaccine, Gardasil®, is effective in men who have sex with men, and also in women between the ages of 27 and 45. The findings were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) meeting in February.

In clinical trials with 598 gay men, Gardasil® was 77.5 % effective in preventing cell changes known as anal intraepithelial neoplasia (AIN) related to the four HPV types covered by the vaccine (HPV 6, 11, 16, and 18, respectively).

Anal cancer is fairly uncommon, and the American Cancer Society estimates about 5,300 new cases occur in the U.S. each year. The CDC says the risk of the disease in gay and bisexual men is 17 times greater than heterosexual men.

Merck also presented data from a study with women ages 27-45 that found Gardasil® was 89% effective in blocking persistent cervical and genital infection from the HPV types included in the vaccine.

This “end of study” data covers 48 months of follow-up with nearly 3,800 subjects, and was submitted to the Food and Drug Administration in late 2009. Gardasil is currently approved for use with females and males ages 9-26, and Merck is seeking to have the vaccine’s indication expanded to include women through age 45. A decision by the FDA is expected by June 2010.

HPV and Men - CDC Fact Sheet
American Cancer Society Detailed Guide to Anal Cancer